Drug-induced lupus: an update on its dermatologic aspects.
Drug-induced lupus erythematosus (DILE) is defined as an entity characterized by clinical manifestations and immunopathological serum findings similar to those of idiopathic lupus but which is temporally related to continuous drug exposure and resolves after discontinuation of the offending drug. Similar to idiopathic lupus, DILE can be divided into systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). Based on the literature review and retrospective analysis of our case series, we focused on the dermatological aspects of DILE. The cutaneous features of drug-induced SLE are protean, including particularly purpura, erythema nodosum and photosensitivity as well as the skin lesions characterizing both urticarial and necrotizing vasculitis. The typical laboratory profile of systemic DILE consists of positive antinuclear antibodies (ANA) and antihistone antibodies, the latter being regarded as the serum marker of this subset. The drugs most frequently implicated in the development of systemic DILE are hydralazine, procainamide, isoniazid and minocycline. Drug-induced SCLE usually presents with annular polycyclic or papulosquamous cutaneous manifestations as in the idiopathic form, but blisters or targetoid lesions mimicking erythema multiforme cannot rarely be associated. The clinical presentation is often generalized, with involvement of the lower legs that are usually spared in idiopathic SCLE. ANA and anti-Ro/SSA antibodies are usually present, whereas antihistone antibodies are uncommonly found. Drugs associated with SCLE include particularly calcium channel blockers, angiotensin-converting enzyme inhibitors, thiazide diuretics, terbinafine and the recently reported tumour necrosis factor (TNF)-alpha antagonists. Drug-induced CCLE is very rarely described in the literature and usually refers to fluorouracile agents or TNF-alpha antagonists. The picture is characterized by the occurrence of classic discoid lesions, but aspects of lupus tumidus can occasionally develop. ANA are demonstrated in around two-thirds of the cases. Management of DILE is based on the withdrawal of the offending drug. Topical and/or systemic corticosteroids and other immunosuppressive agents should be reserved for resistant cases.
Marzano
A V
AV
Department of Anesthesiology, Intensive Care and Dermatological Sciences, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy.
Vezzoli
P
P
Crosti
C
C
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects; D001323:Autoantibodies / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D007538:Isoniazid / Q000009:adverse effects; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D008179:Lupus Erythematosus, Discoid / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D008911:Minocycline / Q000009:adverse effects; D011342:Procainamide / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced / Q000276:immunology / Q000473:pathology
D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D000959:Antihypertensive Agents; D000995:Antitubercular Agents; D001323:Autoantibodies; D006830:Hydralazine; D008911:Minocycline; D011342:Procainamide; D007538:Isoniazid